Genes and environment in type 2 diabetes and atherosclerosis

Slides:



Advertisements
Similar presentations
Ronald A. Codario, MD Assistant Clinical Professor of Medicine
Advertisements

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Lipids 101 Cardiology Board Review Med-Peds Style!
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Understanding blood lipids and glucose How a Healthy Lifestyle can improve your numbers Susan Fullmer, PhD RD Associate Teaching Professor Nutrition, Dietetics,
Cardiovascular Disease in Women Module III: Risk Assessment Tool.
CONTROLLING CARBS AND PREVENTING DISEASE Low carb, obesity, cardiovascular disease and diabetes Jacqueline A. Eberstein, R.N.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Diabetic Dyslipidemia and Atherosclerosis Henry Ginsberg, MD
Global impact of ischemic heart disease World Heart Federation, 2011.
Note Final Exam-please check final schedule Essays due-lateness unacceptable.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
METABOLIC Syndrome: a Global Perspective
DYSLIPIDEMIAS: TYPES I-V Thomas F. Whayne, Jr, MD, PhD, FACC Professor of Medicine (Cardiology) University of Kentucky March 2011.
03/06/231 K June /06/232 Atherosclerosis Etiology Classic Risk Factors Dyslipidemia Low HDL Epidemiological Studies (e.g. Framingham) Genetic.
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
Chapter 15 Cardiovascular Disease Risk Factors and Physical Activity.
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
Metabolic Syndrome Darwin Deen, MD, MS Albert Einstein College of Medicine Gina Lopez, MSII Sophie Davis School of Biomedical Education.
Paul Zimmet & George Alberti
Nutrigenomics KNH 413.
Dyslipidemia CASE 5A. Aling D., 62 years old female who came in for a General Check-up General Data.
Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.
Diabetes Mellitus Introduction to Diabetes Epidemiology.
Size and apolipoprotein composition are the main factors determining atherogenicity of triglyceride-rich particles.
Cholesterol Measurement All adults should have their blood cholesterol measured every 5 years May be in non-fasting state Fasting preferred
HANDBOOK OF DYSLIPIDEMIA AND ATHEROSCLEROSIS Part One Professor Jean-Charles Fruchart Department of Atherosclerosis (Inserm UR545) Pasteur Institute of.
Date of download: 5/31/2016 From: Metabolic Risk Factors Worsen Continuously across the Spectrum of Nondiabetic Glucose Tolerance: The Framingham Offspring.
Presented by Slyter Nutrition Consulting Services.
Data Sources Definitions
Cardiovascular Disease: Risk Factors and Risk Assessment
Therapeutic Lifestyle
Note Final Exam-please check final schedule.
Chapter 7 Metabolic syndrome
Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS
Director, Lipid Research Center The Johns Hopkins Medical Institutions
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
National Cholesterol Education Program
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Chapter 10 Diet and Health
Screening and Monitoring
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Nutrigenomics KNH 413.
Note Final Exam-please check final schedule.
Type 2 diabetes: Overlap of clinical conditions
Nutrigenomics KNH 413.
Nutrigenomics KNH 413.
1 Physical Activity, Health, and Chronic Disease chapter 1 chapter
Nutrigenomics KNH 413.
Note Final Exam-please check final schedule
K June 03 03/06/20 1.
Note Final Exam-please check final schedule.
Chapter 7 LIPIDS IN HEALTH & DISEASE
Note Final Exam-please check final schedule.
Section overview: Cardiometabolic risk reduction
Goals & Guidelines A summary of international guidelines for CHD
CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome
Cardiovascular Disease in Women Module III: Risk Assessment Tool
Nutrigenomics KNH 413.
Nutrigenomics KNH 413.
PROSPER: trial design                                                                                                                                                                 
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Genes and environment in type 2 diabetes and atherosclerosis Figure 57 Not much genetic evolution has occurred in humans in the past 20,000 years. In the Palaeolithic age, our ‘thrifty genotype’ was well-adapted to the high level of physical activity associated with our hunter-gatherer existence. However, this genotype has become redundant in the presence of our sedentary lifestyle and a diet low in fibre and high in animal fats and glucides. In short, our genotype – no longer adapted to our lifestyle – has become a ‘susceptibility genotype’.

Pima Indians Thrifty genes Figure 58 Epidemiological evidence of the ‘thrifty genotype’ becoming a ‘susceptibility genotype’ comes from the study of the Pima Indians. Those maintaining a traditional way of life have little obesity or type II diabetes, while those with the newer, more sedentary way of life have developed high rates of obesity (75%) and type II diabetes (50%).

Aboriginal Canadians Oji-Cree Figure 59 Similarly, rapid change to a sedentary lifestyle in aboriginal Canadians resulted in a tripling of CHD over 20 years.

Obesity, type 2 diabetes, atherosclerosis Figure 60 Thus, the interaction between our current genotype and our present day environment places us at risk of having a phenotype that is highly susceptible to AS.

The Metabolic Syndrome Figure 61 The Metabolic Syndrome (‘Syndrome X’) is the pathological expression of the ‘susceptibility genotype’. It is a disease of the modern Western lifestyle characterized by truncal/visceral obesity, hypertension, hyperinsulinemia, reduced glucose tolerance, and a pro-coagulatory state.

Visceral obesity is associated with a cluster of metabolic abnormalities Figure 62 The Metabolic Syndrome is characterized by the following features of dyslipidemia: high TGs; increased small, dense LDL; low HDL-cholesterol; elevated apo B; pro-inflammatory profile.

The atherogenic triad Figure 63 The traditional ‘atherogenic triad’ of high TGs, high LDL and low HDL is associated with an odds ratio of 4.4 for CHD. However, the newer triad of hyperinsulinemia, elevated apo B, and increased small dense LDL is associated with an odds ratio almost five times greater. Therefore, the Metabolic Syndrome represents a virulent CHD-promoting condition.

PROCAM Study: MI-Incidence according to LDL-cholesterol and triglycerides Figure 64 The PROCAM study identified low HDL-cholesterol as an independent risk factor for MI (in addition to raised TGs and LDL).

70% of men with CHD had a low HDL ≤44mg/dL Framingham Male Offspring 35-54 Figure 65 The importance of HDL-cholesterol as a risk factor was confirmed in the Framingham Male Offspring study. The study showed that almost 70% of men with premature CAD had low HDL (<44 mg/dL) whereas almost 70% had normal or only moderately elevated LDL.